Stimulating wound healing with cold plasma technology: nominated by VGZ Team Plasmacure is incredibly proud that we have been nominated by VGZ Cooperative for the VGZ Award: Healthcare Innovator of the Future!

25 March 2022  – Author: Petra Teunissen. This article was published in the professional journal VoetVak+ for medical and cosmetic foot care.  Infection is one of the most common complications of poorly healing wounds.

This article describes the Tv-broadcast (in Dutch) of October 30, 2021, episode 303. At the end of this news item you will find a link to an English subtitled video about patient Werd van der Horst and diabetes podiatrist Ingrid Ruys.

Medtech start-up Plasmacure is developing an innovative plaster to treat chronically open wounds. Sixty percent are healed within seven weeks. 23 December 2021 – Author: Corine Spaans, published by Innovation Origins.

20 mei 2021 – Auteur: Marc van Bijsterveldt voor ZonMw    Project:  Cold plasma: opportunities for people with wound infections   
Investigator:  Dr. ir. Bouke Boekema, Association of Dutch Burn Centres (ADBC) 
Term:  2014 –

DTW Talks – Starting and growing in Med Tech. Recently Bas Zeper, CEO and founder of Plasmacure was a guest at DTW Talks. On the basis of an impressive example he speaks about positive results of PLASOMA cold plasma treatment on healing of chronic wounds.

Author: Diabetes Fonds, published in ‘Dialoog’, magazine 1 – 2021. You bump your foot, a wound occurs. With diabetes this means double bad luck: wounds heal slower and bacteria have free rein.

We are proud that Plasmacure’s CEO Bas Zeper is one of the selected 6 people that are in the focus of a documentary, Home of… by Brainport Eindhoven. In the documentary that explores how these people see success of Brainport region,

December 2nd 2020 – Author: Corine Spaans, published by Brainport Development. Chronic wounds mainly occur among the elderly. The treatment is fragmented and expensive. There are no specialists like the oncologist for cancer or the internist for diabetes.